Recent Updates
Recently added Catalysts
CBLL Positive Sentiment Score: 75/100

Ceribell to Participate in the Bank of America Securities 2026 Health Care Conference

Key Takeaway: Ceribell, Inc. will participate in the Bank of America Securities 2026 Health Care Conference, featuring CEO Jane Chao and CFO Scott Blumberg in a fireside chat. The event is scheduled for May 13, 2026. Ceribell specializes in advanced diagnostic solutions for neurological conditions, with its FDA-cleared Ceribell System designed for acute-care settings.

Market Sentiment Analysis

POSITIVE FACTORS

  • Ceribell is participating in a prominent health care conference.
  • The company is focused on innovative solutions for neurological conditions.
  • The Ceribell System is FDA-cleared, enhancing its credibility.

Full Press Release Details

SUNNYVALE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, and Scott Blumberg, CFO, will participate in a fireside chat at the upcoming Bank of America Securities 2026 Health Care Conference. The fireside chat will take place on Wednesday, May 13, 2026, at 3:40 p.m. Pacific Standard Time / 6:40 p.m. Eastern Standard Time.

Event: Bank of America Securities 2026 Health Care ConferenceDate: Wednesday, May 13, 2026Time: 3:40 p.m. PST / 6:40 p.m. EST

A live and archived webcast of the presentation will be available in the "Investor Relations" section of the Ceribell website athttps://investors.ceribell.com/.
About CeriBell, Inc.Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute-care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared for use in detecting seizure and delirium in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visitwww.ceribell.comor follow the company onLinkedIn.

Investor ContactBrian JohnstonGilmartin GroupInvestors@ceribell.com

Media ContactBrian PricePress@ceribell.com

Frequently Asked Questions

When is Ceribell participating in the conference?

Ceribell will participate in the conference on May 13, 2026.

Who will represent Ceribell at the conference?

CEO Jane Chao and CFO Scott Blumberg will represent Ceribell.

What is the focus of Ceribell's technology?

Ceribell focuses on diagnosing and managing serious neurological conditions.

Is the Ceribell System FDA-cleared?

Yes, the Ceribell System is FDA-cleared for use in acute-care settings.

Last updated: Apr 29, 2026